Brain natriuretic peptide detects cardiac abnormalities in mass screening

European Journal of Clinical Investigation

Volumn 37, Issue 4, 2007, Pages 257-262

  Takase, H ^a   Toriyama, T ^a   Sugiura, T ^b,c   Takahashi, A ^b,c   Sugiyama, M ^b,c   Ohashi, M ^b,c   Ueda, R ^b,c   Dohi, Y ^b,c  

^a Enshu General Hospital   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Brain natriuretic peptide; Cardiac abnormalities; Mass screening

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEALTH PROGRAM; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; MASS SCREENING; MEDICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES;

EID: 33947301184     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01780.x     Document Type: Article

References (29)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.
2. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
3. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990;70:665-99.
4. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
5. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Hosoda K et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-80.
6. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda S et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996;28:1234-42.
7. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786- 92.
8. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
9. Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hyperten 1993;7:245-50.
10. Watanabe M, Murakami M, Furukawa H, Nakahara H. Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease? Int J Cardiol 2004;96:21-4.
11. Jourdain P, Bellorini M, Funck F, Fulla Y, Guillard N, Loiret J et al. Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. Eur J Heart Fail 2002;4:263-7.
12. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
13. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
14. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
15. McDonagh T, Robb S, Murdoch D, Morton JJ, Ford I, Morrison CE et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
16. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8.
17. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5.
18. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-9.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
21. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamida K, Yoshihara F et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004;44:420-8.
22. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223-5.
23. Tsuji H, Nishino N, Kimura Y, Yamada K, Nukui M, Yamamoto S et al. Haemoglobin level influences plasma brain natriuretic peptide concentration. Acta Cardiol 2004;59:527-31.
24. Takase H, Toriyama T, Sugiura T, Ueda R, Dohi Y. Brain natriuretic peptide in the prediction of recurrence of angina pectoris. Eur J Clin Invest 2004;34:79-84.
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
26. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic Volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
27. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. Circulation 2002;105:595-601.
28. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
29. Segawa T, Nakamura M, Itai K, Onoda T, Okayama A, Hiramori K. Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. Int Heart J 2005;46:465-75.